ESEmilie V. J. van Limburg Stirum

Emilie V. J. van Limburg Stirum

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emilie V. J. van Limburg Stirum has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prenatal 17‐Alpha‐Hydroxyprogesterone Caproate Exposure in Twins and Childhood Outcomes: 14‐Year Follow‐Up of a Randomised Trial

    by Emilie V. J. van Limburg Stirum, Marjon A. de Boer, A. C. J. Ravelli, Rik van Eekelen, Aleid G. Leemhuis, Martijn J. J. Finken, Cornelieke S. H. Aarnoudse‐Moens, Anneloes L. van Baar, Noor E. Simons, Rebecca C. Painter, et al.

    Objective: Long‐term child outcomes after intra‐uterine exposure to 17‐alpha‐hydroxyprogesterone caproate (17‐OHPC) versus placebo. Design: Follow‐up of the AMPHIA randomised controlled trial assessing neonatal outcomes after weekly 17‐OHPC injections compared to placebo in multiple pregnancies. Setting: Multicentre. Population or Sample: Children born in the AMPHIA study. Methods: Children were assessed at 11–14 years of age by record linkage and through self‐reported, parental and teacher questionnaires. Mean differences or odds ratios (OR) with 95% confidence intervals (95% CI) were calculated with cluster robust standard errors for twins and adjustment for confounders using inverse probability weighting (IPW). Main Outcome Measures: Child mortality, educational attainment, cognition, behaviour, gender identity, general health, and a composite of abnormal development. Results: Up to 14 years, 60/1356 children had died ( n = 24 17‐OHPC and n = 36 placebo (OR 0.75 95% CI 0.36–1.53)). Record linkage was completed for 1027/1296 (79%) surviving children ( n = 517 17‐OHPC and n = 510 placebo). No significant difference was found regarding educational attainment. Detailed developmental outcomes through questionnaires were collected for 303/1296 (23%) surviving children ( n = 159 17‐OHPC and n = 144 placebo). No differences in cognition, behaviour, gender identity, and general health up to 14 years of age were found between both groups. The composite of abnormal development did not differ between 17‐OHPC (23.3%) and placebo (20.1%) groups (OR 1.31 95% CI 0.66–2.56). Conclusion: In offspring of women with a multiple pregnancy, the use of 17‐OHPC in pregnancy is unlikely to provide positive or negative effects on child outcome related to mortality, educational attainment, cognition and behaviour.

  • Open Access

    Additional risk stratification in women with a history of spontaneous preterm birth and a midtrimester cervical length > 25 millimeters

    by Emilie V. J. van Limburg Stirum, Sofie H. Breuking, Charlotte E. van Dijk, Janneke van ’T Hooft, Brenda M. Kazemier, Annemijn A. de Ruigh, Martijn A. Oudijk, Eva Pajkrt, Marjon A. de Boer

    Purpose: To determine whether there is an association between cervical length > 25 millimeters (mm) and a decrease in cervical length before 24 weeks of gestation with an increased risk of recurrent spontaneous preterm birth (sPTB).” Methods: This retrospective cohort study includes women with a singleton pregnancy, a previous sPTB before 34 weeks of gestation, serial cervical length measurements and a shortest midpregnancy cervical length of > 25 mm. Participants received care according to local protocols for the prevention of preterm birth in two academic hospitals in the Netherlands between February 2005 and September 2021. Exclusion criteria were fetal structural anomalies, signs of threatened preterm birth or treatment with a cerclage or pessary. Cervical length measurements were grouped in three timepoints in pregnancy that were chosen a priori: 14 + 0 to 18 + 6 weeks (CL1); 19 + 0 to 20 + 6 weeks (CL2); and 21 + 0 to 23 + 6 weeks (CL3). Outcome measures included percentage of sPTB (< 37, < 34 and < 28 weeks of gestation) with 95% confidence intervals (95% CI) and Odds Ratio’s (OR). Association between decrease in cervical length and sPTB were calculated using logistic regression. Results: In total, 469 pregnancies were included. Overall, sPTB recurred in 21.1% (95% CI 17.4–24.8%), 9.0% (95% CI 6.4–11.6%) and 1.9% (95% CI 0.7–3.2%) before 37, 34 and 28 weeks of gestation, respectively. Women with a cervical length of > 25–30 mm in CL3 were at higher risk to deliver before 37 weeks, compared to women with a cervical length > 30 mm (44.7% versus 18.5%, OR 3.6, 95% CI 1.91–6.66). The decrease in cervical length between timepoint CL1, CL2 and CL3 had no association with a recurrent sPTB. Conclusions: Women with a history of sPTB before 34 weeks of GA and a cervical length of > 25–30 mm before the 24 weeks of gestation have an almost four times higher risk for a recurrent sPTB, compared to those with a longer cervical length. No association was found between decrease in cervical length and the risk of sPTB. Future studies should assess whether women with a history of sPTB and a cervical length of > 25–30 mm benefit from cerclage and cutoff values could be revised accordingly.

  • Open Access

    Long‐term child outcomes after prenatal aspirin exposure: A 4‐year follow‐up of a randomized controlled trial (the APRIL study)

    by Emilie V. J. van Limburg Stirum, Janneke van ’T Hooft, Anadeijda J. E. M. C. Landman, Martijn J. J. Finken, Anita C. J. Ravelli, Aleid G. Leemhuis, Eva Pajkrt, Martijn A. Oudijk, Marjon A. de Boer

    Objective: To identify the long‐term child outcomes after prenatal aspirin exposure. Methods: This study is a follow‐up of a randomized controlled trial (RCT) evaluating low‐dose aspirin in the prevention of recurrent spontaneous preterm labor (the APRIL study) comparing aspirin 80 mg daily ( n = 194) to placebo ( n = 193) in singletons. Children were assessed at 4 years corrected age using the Ages and Stages Questionnaire (third edition, ASQ‐3) and the Strengths and Difficulties Questionnaire (SDQ) for (neuro)development and behavioral outcomes, respectively. Data on mortality, general health, growth and a composite of abnormal child outcome or mortality were also collected. Analyses were performed reporting odds ratio (OR) and 95% confidence intervals (CIs). Results: Eight children were deceased until 4 years follow‐up (all perinatal deaths; n = 6 in aspirin and n = 2 in the placebo group). We included 231/379 (60.9%) children: 111/231 in the aspirin and 120/231 in the placebo groups. Total ASQ‐3 score was higher in the aspirin group (mean 259.3 vs. 248.3, mean difference 10.96, 95% CI: 0.17–21.76). The rate of children with an ASQ‐3 score of ≥1SD below the normative data did not differ between groups (35.2% vs. 47.4%; OR 0.60, 95% CI: 0.33–1.09), nor did a score on the SDQ ≥80th centile (18.3% vs. 14.7%; OR 1.30, 95% CI: 0.64–2.66). General health, growth and the composite outcome of abnormal child development or mortality did not significantly differ between groups. Conclusion: We found no harmful effects of daily prenatal exposure to aspirin 80 mg. Our findings contribute to the existing data confirming the safety of low‐dose aspirin use in pregnancy.


  • Open Access

    Atosiban versus placebo in the treatment of threatened preterm birth between 30 and 34 weeks gestation: study protocol of the 4-year APOSTEL 8 follow-up

    by Larissa van der Windt, Job Klumper, Emilie V J van Limburg Stirum, Janneke van 'T Hooft, Madelon van Wely, Aleid G van Wassenaer-Leemhuis, Eva Pajkrt, Martijn A Oudijk

    Introduction Currently, the majority of women worldwide with threatened preterm birth are treated with tocolytics. Although tocolytics can effectively delay birth for 48 hours, no tocolytic drug has convincingly been shown to improve neonatal outcomes and effects on long-term child development are unknown. The aim of this follow-up study of a placebo controlled randomised trial is to investigate the long-term effects of atosiban administration in case of threatened preterm birth on child’s neurodevelopment and behaviour development, overall health and mortality. Methods and analysis This protocol concerns a follow-up study of the multicentre randomised double-blind placebo controlled APOSTEL 8 trial (NL61439.018.17, EudraCT-number 2017-001007-72). In this trial, women with threatened preterm birth (between 30 and 34 weeks of gestation) defined as uterine contractions with (1) a cervical length of Ethics and dissemination The Medical Research Ethics Committee from Amsterdam UMC confirmed that de Medical Research Involving Human Subjects Act (Dutch WMO-law) did not apply to our study (W21_386 # 21.431). Results will be published in a peer-reviewed journal and shared with stakeholders and participants. This protocol is published before analysis of the results.


  • Open Access

    Pessary or progesterone to prevent preterm birth in women with short cervical length: protocol of the 4–6 year follow-up of a randomised controlled trial (Quadruple-P)

    by Emilie V J van Limburg Stirum, Larissa I van der Windt, Charlotte E van Dijk, Anneloes L van Baar, Aleid G Leemhuis, Madelon van Wely, Marjon A de Boer, Janneke van 'T Hooft, Martijn A Oudijk, Eva Pajkrt

    Introduction Vaginal progesterone and a cervical pessary are both interventions that are investigated for the prevention of preterm birth (PTB). Thus far, beneficial or harmful effects of these interventions on long-term child health and development are described, but evidence is not robust enough to draw firm conclusions. With this follow-up study, we intent to investigate if progesterone or a pessary is superior for the prevention of PTB considering the child’s health at 4–6 years of corrected age. Methods and analysis This study is a follow-up study of the Quadruple-P trial; a multicentre, randomised clinical trial (NL42926.018.13, Eudractnumber 2013-002884-24) which randomises women with an asymptomatic midtrimester short cervix to daily progesterone or a pessary for the prevention of PTB. All children born to mothers who participated in the Quadruple-P study (n=628 singletons and n=332 multiples) will be eligible for follow-up at 4–6 years of corrected age. Children will be assessed using parental questionnaires. Main outcomes are child (neuro)development and behaviour. Other outcomes include child mortality, growth and general health. A composite of adverse child outcomes will be compared between the progesterone and pessary groups reporting OR and the corresponding 95% CI. Analyses will be performed separately for singletons and multiples and using the intention-to-treat approach. Ethics and dissemination The Medical Research Ethics Committee from Amsterdam UMC confirmed that de Medical Research Involving Human Subjects Act (WMO) did not apply to our study (W20_481 #20.531). Results will be published in a peer-reviewed journal and shared with stakeholders and participants. This protocol is published before analysis of the results. Trial registration number Dutch Trial Register (NL9646).


  • Open Access

    Long-term outcomes following antenatal exposure to low-dose aspirin: study protocol for the 4-year follow-up of the APRIL randomised controlled trial

    by Anadeijda J E M C Landman, Emilie V J van Limburg Stirum, Janneke van 'T Hooft, Aleid G Leemhuis, Martijn J J Finken, Anneloes L van Baar, Tessa J Roseboom, Anita C J Ravelli, Madelon van Wely, Jaap Oosterlaan, et al.

    Introduction The use of low-dose aspirin by pregnant women to prevent preterm pre-eclampsia is gradually increasing. The administration of aspirin during pregnancy improves perinatal outcome, which could translate into improved child outcome in the long term. However, antenatal exposure to aspirin could have adverse effects on child development that may manifest later in life. The aim of this follow-up study is to assess the long-term effects of antenatal exposure to low-dose aspirin compared with placebo on survival, (neuro)development, behaviour and general health at 4 years corrected age. Methods and analysis This is a follow-up study of the Dutch double-blind randomised controlled APRIL trial which assessed the effectiveness of treatment with aspirin (80 mg daily) compared with placebo for the prevention of preterm birth in women with a previous spontaneous preterm birth. Treatment was initiated before 16 weeks of gestation and continued until 36 weeks or birth. We aim to follow-up all 379 children born to women who participated in the APRIL trial and survived the neonatal period, at the corrected age of 4 years. The main outcomes are (neuro)development as assessed by the Ages and Stages Questionnaire, and behaviour as assessed by the Strength and Difficulties Questionnaire. Additional outcomes include mortality, growth and general health from birth up to 4 years, and a composite outcome including mortality, abnormal (neuro)development and problem behaviour. Analyses will be performed by intention-to-treat using a superiority design. Ethics and dissemination Institutional Review Board approval was obtained from the Medical Research Ethics Committee from Amsterdam Medical Center (no. W20 289#20.325). The results will be published in a peer-reviewed journal and presented at conferences. Trial registration number The APRIL trial (NTR5675, NL5553; EudraCT number 2015-003220-31) and the APRIL follow-up study (NL8950) are registered in the Dutch trial register. The study is funded by the Amsterdam Reproduction & Development research institute.


  • Open Access

    Consequences of cervical pessary for subsequent pregnancy: follow‐up of randomized clinical trial (ProTWIN)

    by E. V. J. van Limburg Stirum, S. J. Zegveld, N. E. Simons, M. A. de Boer, E. Pajkrt, B. W. J. Mol, M. A. Oudijk, J. van 'T Hooft

    Objective: To evaluate the effect of cervical pessary, as a strategy to prevent preterm birth (PTB), on the outcome of subsequent pregnancy and maternal quality of life 4 years after the index twin pregnancy.Methods: Between 2009 and 2012, the ProTWIN trial randomized women with a multiple pregnancy to pessary use vs standard care for the prevention of PTB. The trial showed no benefit in unselected women with a twin pregnancy, but showed a 60% reduction in poor perinatal outcomes in favor of the pessary group in the subgroup of women with a mid‐trimester short cervix (cervical length < 38 mm). All women were invited to participate in a follow‐up study 4 years after their participation in the ProTWIN trial. In this follow‐up study, maternal quality of life was assessed using the EQ‐5D‐3L questionnaire and women were asked separate questions about subsequent pregnancies. Results were compared between women who were randomized to the pessary vs the control group in the ProTWIN trial by calculating relative risk (RR) and 95% CI. Subgroup analysis was performed for women with a mid‐trimester short cervix (cervical length < 38 mm).Results: Of the 813 women included in the ProTWIN trial, 408 (50.2%) participated in this follow‐up study, comprising 228 randomized to the pessary group and 180 to the control group in the original trial. The median interval between participation in the ProTWIN trial and participation in this follow‐up study was 4.1 (interquartile range (IQR), 3.9–7.1) years. Ninety‐eight (24.0%) participants tried to conceive after their participation in the ProTWIN trial. Of those, 22 (22.4%) women did not have a subsequent pregnancy (no difference between pessary and control groups), seven (7.1%) women had at least one miscarriage but no live birth, and 67 (68.4%) women had at least one live birth (35 in the pessary vs 32 in the control group; RR, 0.93 (95% CI, 0.8–1.07)). In two women, the pregnancy outcome was unknown. Preterm delivery (< 37 weeks of gestation) of the first live birth occurred in three women in the pessary vs one woman in the control group (all singleton; RR, 2.57 (95% CI, 0.28–23.44)). No differences were found between the pessary and control groups in the subgroup of women with mid‐trimester short cervix, but the numbers analyzed were small. The median health state index score was 0.95 (IQR, 0.82–0.95), with no difference between the pessary and control groups.Conclusion: Our findings suggest that there are no long‐term effects of pessary use on the outcome of subsequent pregnancies and maternal quality of life. Data on obstetric outcome were limited due to the small numbers. © 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.